GLRA1: A Potential Drug Target and Biomarker for Various Diseases

Target Name: GLRA1

NCBI ID: G2741

GLRA1

GLRA1: A Potential Drug Target and Biomarker for Various Diseases

GLRA1 (G protein-coupled receptor type 1) is a protein that is expressed in many different tissues throughout the body. It is a member of the G protein-coupled receptor family, which is a large family of transmembrane proteins that play an important role in cellular signaling. GLRA1 is one of the most well-studied G protein-coupled receptors, and a number of different drugs that are currently in development target GLRA1. In this article, we will explore GLRA1 as a drug target and discuss some of the current research into its potential as a therapeutic.

GLRA1 is a transmembrane protein that is expressed in many different tissues throughout the body, including the brain, heart, kidneys, and pancreas. It is a member of the G protein-coupled receptor family, which is a large family of transmembrane proteins that play an important role in cellular signaling. The G protein-coupled receptor family includes over 700 different proteins, and many of these proteins are involved in signaling various types of signaling cascades that are involved in a wide range of physiological processes.

GLRA1 is involved in a number of different signaling pathways. For example, it is involved in the regulation of pain perception, and has been shown to play a role in the development of chronic pain conditions. It is also involved in the regulation of inflammation, and has been shown to play a role in the development of inflammatory diseases. In addition, GLRA1 is involved in the regulation of stem cell proliferation and differentiation, and has been shown to play a role in the development of cancer.

GLRA1 is also a drug target for several different classes of drugs. Many of these drugs work by interacting with GLRA1 and modulating its activity. For example, some drugs that are currently in development to treat anxiety and depression target GLRA1, and are thought to work by modulating its activity to increase the activity of neurotransmitters such as dopamine and serotonin. Other drugs that are being developed to treat pain target GLRA1 and are thought to work by modulating its activity to increase the activity of pain-sensitive neurons.

In addition to its potential as a therapeutic target, GLRA1 is also a promising biomarker for the diagnosis of various diseases. For example, some researchers have shown that GLRA1 is downregulated in the brains of individuals with Alzheimer's disease, and that this downregulation is associated with the development of the disease. Other researchers have also shown that GLRA1 is downregulated in the livers of individuals with cancer, and that this downregulation is associated with the development of the disease. These findings suggest that GLRA1 may be a useful biomarker for the diagnosis and treatment of various diseases.

Overall, GLRA1 is a protein that is involved in a number of different signaling pathways and is a potential drug target for several different classes of drugs. While more research is needed to fully understand its role in cellular signaling and its potential as a therapeutic, GLRA1 is a promising target for the development of new treatments for a wide range of diseases.

Protein Name: Glycine Receptor Alpha 1

Functions: Glycine receptors are ligand-gated chloride channels (PubMed:23994010, PubMed:25730860). Channel opening is triggered by extracellular glycine (PubMed:2155780, PubMed:7920629, PubMed:14551753, PubMed:16144831, PubMed:22715885, PubMed:22973015, PubMed:25973519, PubMed:9009272). Channel opening is also triggered by taurine and beta-alanine (PubMed:16144831, PubMed:9009272). Channel characteristics depend on the subunit composition; heteropentameric channels are activated by lower glycine levels and display faster desensitization (PubMed:14551753). Plays an important role in the down-regulation of neuronal excitability (PubMed:8298642, PubMed:9009272). Contributes to the generation of inhibitory postsynaptic currents (PubMed:25445488). Channel activity is potentiated by ethanol (PubMed:25973519). Potentiation of channel activity by intoxicating levels of ethanol contribute to the sedative effects of ethanol (By similarity)

The "GLRA1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GLRA1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets